Saudi Chemical Co.

Saudi Chemical Co.

TTADAWUL:2230
5.80
SAR
-0.46
(-7.35%)
0.42EPS
19.60P/E
6.90BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.7
2.94
2.85
2.54
2.93
3.5
3.5
3.92
4.05
4.38
5.76
7.56
8.16
8.35
Basic EPS, GAAP
0.36
0.34
0.3
0.16
0.17
0.14
0.04
0.09
0.08
0.1
0.22
0.35
0.4
0.42
Free Cash Flow per Basic Share
0.09
0.26
-1.41
-0.01
0.17
-0.08
-0.26
-0.28
-0.21
0.53
0.42
-0.34
0.53
0.8
Dividend per Share
0.26
0.28
- -
- -
- -
- -
- -
- -
0.05
0.05
0.05
0.05
0.05
- -
Book Value per Share
1.78
1.83
1.9
1.8
- -
1.81
1.84
1.93
1.92
1.97
2.14
2.48
2.83
2.92
Tangible Book Value per Share
1.22
1.26
1.9
1.8
- -
1.8
1.28
1.37
1.35
1.24
1.41
1.74
2.09
2.18
Basic Weighted Avg Shares
843
844
844
843
843
843
843
843
843
843
843
843
843
843
Sales/Revenue/Turnover
2,275
2,484
2,410
2,143
2,474
2,949
2,949
3,306
3,411
3,696
4,855
6,375
6,881
7,040
Operating Margin (%)
13.87
12.66
11.75
9.05
7.58
6.24
4.26
5.23
4.18
4.8
6.54
6.85
6.96
6.73
Depreciation Expense
19
18
- -
- -
- -
- -
40
47
46
45
46
54
69
66
Net Income, GAAP
301
284
251
135
143
115
33
74
70
80
183
291
335
352
Effective Tax Rate (%)
7.37
8.95
- -
- -
- -
18.82
49.52
30.67
34.05
29.06
15.46
12.34
12.34
12.64
Profit Margin (%)
13.21
11.41
10.4
6.31
5.78
3.89
1.11
2.24
2.04
2.17
3.77
4.57
4.87
5
Working Capital
859
829
768
723
1,646
670
580
617
493
706
732
981
1,176
1,208
LT Debt
- -
- -
- -
- -
- -
110
109
307
365
753
653
600
477
417
Total Equity
1,506
1,548
1,608
1,520
- -
1,529
1,560
1,637
1,625
1,668
1,809
2,103
2,397
2,482
Return on Invested Capital (%)
17.35
15.57
13.79
- -
- -
- -
2.23
3.36
2.79
3.91
9.02
0.01
12.07
8.81
Return on Capital (%)
18.06
15.64
12.6
- -
- -
- -
2.14
3.21
2.78
3.58
8.42
11.08
11.5
11.11
Return on Common Equity (%)
20.57
18.64
15.94
8.68
- -
- -
2.14
4.65
4.28
4.9
10.57
14.97
14.99
15.08

Capital Structure

SAR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
706
733
723
LT Borrowings
446
410
383
LT Finance Leases
31
24
34
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
843
843
843
Market Capitalization
5,405
6,830
6,897

Working Capital

SAR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,460
4,343
4,508
Cash, Cash Equivalents & STI
118
211
145
Accounts Receivable, Net
2,631
2,509
2,686
Inventories
1,543
1,357
1,398
Total Current Liabilities
3,284
3,113
3,300
Payables & Accruals
- -
- -
- -
ST Debt
706
733
723
Deferred Revenue
- -
- -
- -

Growth Rates

SAR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.11%
14.01%
Free Cash Flow
-246.23%
-166.28%
-255.95%
Net Income, GAAP
20.54%
42.33%
15.13%
Sales/Revenue/Turnover
11.78%
16.43%
7.93%
Total Cash Common Dividend
- -
- -
0.02%

Quarterly Revenue

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,645
1,615
1,354
1,762
6,375
2025
1,644
1,766
1,788
1,683
6,881
2026
1,727
1,842
- -
- -
- -

Quarterly Earnings Per Share

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.09
0.09
0.06
0.35
2025
0.1
0.08
0.1
0.11
0.4
2026
0.1
0.1
- -
- -
- -

Quarterly Dividends Per Share

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.05
2026
- -
- -
- -
- -
- -

Company Description

CEO
Abdulsalam Musfer Al Ghamdi
Full Time Employees
300
Sector
Process industries
Industry
Industrial specialties
Address
P.O. Box 2665 Riyadh Riyadh Province Saudi Arabia 11482
IPO Date
May 6, 2001
Business
Saudi Chemical Holding Company (2230.SR), founded in 1972 and headquartered in Riyadh, Saudi Arabia, manufactures and sells explosives and related products for civil and military applications; trades medicines, medical supplies, pharmaceuticals, medical and surgical equipment, cosmetics, perfumes, and beauty products; and produces ammonium nitrate. The company operates through three main segments—Explosives, Medicine and Medical Supplies, and Ammonium Nitrate Production—with products including electronic detonators, blasting agents, initiation systems, seismic explosives, and accessories, serving domestic markets in Saudi Arabia via factories in Riyadh, Jeddah, and the Eastern Province, as well as exporting to Gulf, Arab, and other countries. Subsidiaries such as Saudi Chemical Company Ltd., Suez International Nitrate Company, Saudi International Trading Company (SITCO Pharma), AJA Pharmaceutical Industries Ltd., and Chemical Commercial Investment Company Ltd. support its diversified operations in chemicals, pharmaceuticals, and defense-related industries. Recent developments include a December 2024 memorandum of understanding signed by subsidiary Saudi Chemical Company Limited with Dyno Nobel to establish a production facility; a partnership with the National Company for Military Industries (NCMS) in February 2024 to develop defense technologies; and a January 2024 agreement to build an ammonium nitrate and nitric acid facility in Ras Al-Khair for mining and defense applications. In December 2023, subsidiary AJA Pharmaceuticals entered a binding agreement with Dr. Reddy’s Laboratories for licensing three injection products across Saudi Arabia and GCC countries; earlier that year, it signed an MoU with Moxico Resources and Ajlan & Bros for blasting services at the Al-Khunayqiyah mine. Additional recent moves encompass executive changes, including the resignation of former CEO Thamer Mohmmed Al Muhid and appointment of Abdulsalam Musfer Al Ghamdi; board approval for subsidiary ownership restructuring; and multiple pharmaceutical MoUs with partners like Remedica, Bioventure, and Lagap for product co-development and commercialization.